Biognosys is the world leader in the application of next-generation proteomics solutions to accelerate your research and drug development timelines.

The recent success of immunotherapy has demonstrated the utility of harnessing the immune response for treating cancer and autoimmune disease. Deep quantitative proteomics offers the ability to go beyond known immunological markers and identify novel pathways and proteins that are implicated in the response to immunotherapy.

Here are a few examples of how Biognosys has applied proteomics to address key questions in the immune response to aid in the understanding of disease and the development of novel therapeutics.

Immune Cell Profiling

High-dimensional proteomic characterization of immune cell phenotypes

Immune cells are highly heterogeneous, requiring careful analysis at the level of small subsets or single cells. In this study, we used Biognosys’ Discovery Proteomics to provide a high-dimensional phenotypic characterization of sorted immune cell populations.

Going far beyond the known cell surface markers used in affinity-based approaches, we were able to identify thousands of novel proteins and pathways that distinguish specific immune cell subsets. This detailed proteomic data enables an in-depth analysis of the processes driving immune cell activation and suppression.


Case Study: High-Dimensional Proteomic Characterization of Immune Cell Phenotypes

Applications: Biomarker Discovery

Mechanism of Action

Profiling of the proteomic response to therapy in animal models

Proteomic profiling of tissue or tumor samples from animal models of disease reveals detailed information about the proteins and pathways involved in response to therapy.

For example, Biognosys’ Discovery Proteomics was used to investigate the role of immune cell depletion in the response to PD-1 blockade in syngeneic mouse models.


Case study: Mechanism of Action of Immunotherapy in Syngeneic Mouse Models

Application: Mechanism of Action Studies

Small Molecule Target Deconvolution

Proteome-wide characterization of the binding specificity and selectivity of small molecules

Biognosys’ drug Target Deconvolution approach Limited Proteomics Mass Spectrometry (LiP-MS) can effectively identify protein drug targets and characterize their binding properties in complex proteomes without the need for compound modification or labeling.

In this specific example, LiP-MS was used to distinguish the specificity and selectivity of different kinase and phosphatase inhibitors.


Case Study: Target Deconvolution of Drug Specificity and Selectivity

Publication: A machine-learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes (Nature Communications, 2020)

Technology Video: LiP-MS: A Novel Target Deconvolution Approach

Application: Target Deconvolution


«The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.»

Thomas Knoblauch
Laboratory Manager, Bayer

Let us help you do great proteomics!

Please click here to contact us.